Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allos Therapeutics prices public offering of 7.75 million shares
The company has granted the underwriter a 30-day option to purchase up to an additional 1.16 million shares to cover over-allotments, if any. UBS Investment Bank is the
The company has granted the underwriter a 30-day option to purchase up to an additional 1.16 million shares to cover over-allotments, if any. UBS Investment Bank is the
James White, chief executive, osmetech plc, said: “We are delighted that Fisher HealthCare has partnered with Osmetech, highlighting the attraction of our eSensor XT-8 platform. Fisher HealthCare has
A member of the Institute of Medicine of the National Academy of Sciences and its committees on Human Embryonic Stem Cell Research and on Women’s Health Research, Adashi
Engineering and construction (E&C) sector material and equipment costs to decrease by end of 2009 or early next year, as per Fluor’s annual materials outlook study; copper, nickel
Under the terms of the financing agreement, Aeolus received $1.5 million in gross proceeds in exchange for 5.35 million shares of Aeolus Pharmaceuticals common stock, and five year
This extends Idaho Technology’s ongoing program to license its intellectual property portfolio in cooperation with Roche Diagnostics. The agreement follows a series of intellectual property licensing agreements with
Caphosol is also indicated for hyposalivation and xerostomia irrespective of the cause. Bryan Morton, president and CEO of Eusa Pharma, said: “Caphosol’s introduction into the key French, German,
Infinity Pharmaceuticals has initiated a Phase II clinical trial of IPI-504, its lead heat shock protein 90 inhibitor, in combination with Herceptin in patients with human epidermal growth
The Osny business provides current good manufacturing practices development and manufacturing services for hormonal and other high potent drugs in oral dose forms that are either approved for
Dyax has received a complete response letter from the FDA pertaining to the company’s biologic license application for DX-88 for the treatment of acute attacks of hereditary angioedema.